Loading...
Loading...
ETNB| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.2M |
| Operating Expense | 41.2M |
| Operating I/L | -41.2M |
| Other Income/Expense | 4.8M |
| Interest Income | 5.7M |
| Pretax | -36.4M |
| Income Tax Expense | 3.9M |
| Net Income/Loss | -40.2M |
89bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapies for liver and cardio-metabolic diseases. Its primary focus is on pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21, designed for the treatment of nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company generates revenue through the development and potential commercialization of these innovative therapies, aiming to address unmet medical needs in these disease areas.
